MENTALHEALTH.INFOLABMED.COM - In a significant leap forward for cancer treatment, patients nationwide can now benefit from a revolutionary under-the-skin injection, a development poised to replace lengthy intravenous infusions. This new immunotherapy jab, now available on the NHS, offers a more convenient and efficient way to administer pembrolizumab, a drug known commercially as Keytruda. The subcutaneous injection promises to dramatically cut down treatment times, potentially by up to 90%, thereby reducing the burden of extended hospital stays and boosting NHS productivity.
The innovative injectable form of pembrolizumab is a game-changer, capable of treating a wide array of 14 different cancer types. This includes prevalent forms such as lung cancer, breast cancer, head and neck cancers, and cervical cancer.
The drug works by empowering the patient's own immune cells to identify and eliminate cancer cells, offering a more targeted and potentially less arduous therapeutic approach. By reducing the time patients spend in hospital, this advancement is not just about clinical efficacy but also about significantly enhancing their quality of life during a challenging period.
This shift towards a ready-to-administer subcutaneous injection represents a considerable operational improvement for healthcare providers. Currently, hospital pharmacy teams are tasked with the intricate and time-consuming preparation of intravenous bags under strictly sterile conditions.
Transitioning to a pre-prepared, injectable form of the drug will free up valuable preparation time and clinic capacity. Approximately 14,000 patients in England begin pembrolizumab therapy each year, and the expectation is that the majority will now transition to this more user-friendly subcutaneous version.
The administration of this new jab is designed for maximum convenience. Depending on the specific cancer type, patients will receive the injection either every three weeks, taking just one minute to administer, or every six weeks, with a two-minute injection time.
This starkly contrasts with the current intravenous infusions that can often take up to two hours per session. This dramatic reduction in treatment duration allows patients to reclaim significant portions of their day, minimizing disruption to their personal lives and commitments.
Developed by Merck, pembrolizumab functions by inhibiting the PD-1 protein. This protein acts as a natural brake on the immune system, preventing it from attacking healthy cells.
By blocking PD-1, pembrolizumab effectively releases the brakes, enabling the immune system to more effectively recognize and launch an attack against cancer cells. It is important to note that patients who are currently receiving pembrolizumab alongside other intravenous treatments may continue with their infusion if deemed clinically appropriate by their healthcare team.
The positive impact of this innovation has been met with considerable enthusiasm from healthcare professionals. Peter Johnson, national clinical director for cancer at NHS England, described the immunotherapy as a "lifeline for thousands of patients." He highlighted the remarkable speed of the new jab, stating, "it’s fantastic that this new rapid jab can now take just a minute to deliver – meaning patients can get back to living their lives rather than spending hours in a hospital chair." This sentiment underscores the dual benefit of the treatment: improved patient experience and enhanced healthcare system efficiency.
Johnson further elaborated on the broader implications, noting, "Managing cancer treatment and regular hospital trips can be really exhausting, and not only will this innovation make therapy much quicker and more convenient for patients, it will also help free up vital appointments for NHS teams to treat more people and continue to bring down waiting times."
